Skip to content
Search

Latest Stories

Sidharth Malhotra starrer Thadam remake put on a back burner?

Murtuza Iqbal

Earlier this year, it was announced that Sidharth Malhotra will be seen in the Hindi remake of Tamil film Thadam which will be directed by debutant Vardhan Ketkar. However, according to a report in Bollywood Hungama, the film has been put on a backburner.


A source told the portal, “Sidharth was very excited to act in a double role thriller, and however, the lockdown gave him the time to introspect his choices. He felt that the adaptation was not up to the mark and hence, from August-end, he sat down on the script himself with his director, Vardhan Ketkar. They churned out multiple drafts for the adaptation, however; none of them could fit well as per the Hindi sensibilities. Sid feels the audience consumption pattern for films will change in the pandemic and doesn't want to sign on for anything that he has even the slightest of the doubt on, as he feels responsible about the content he gets out for his fans and cine-goers. That’s when Sidharth and his producer partners, Murad Khetani and Bhushan Kumar decided to put the film on hold.”

“Sid is committed to do a film for Murad Khetani and Bhushan Kumar, and there will be more clarity by March-end about the project they are collaborating on. While Thadam has been put on hold for the time being, you never know, if they manage to pull off a miracle by reworking the script for the Pan-Indian audience. But as things stand at present, Thadam is on the back burner,” added the source.

Meanwhile, reportedly, Sidharth is gearing up to play a spy in a film which will be produced by Amar Butala and directed by ad filmmaker Shantanu Bagchi. He is also awaiting the release of Shershaah.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less